HCV: Continuing Advances From Individual Cure to Disease Elimination
Source: HCV: Continuing Advances From Individual Cure to Disease Elimination

Table of Contents



HCV: Continuing Advances From Individual Cure to Disease Elimination

In this downloadable slideset, Gregory Dore, MBBS, PhD, FRACP, MPH; Graham R. Foster, FRCP, PhD; Ira M. Jacobson, MD; and Norah Terrault, MD, MPH, review strategies for eliminating HCV infection, both at the individual level and at the population level. The slideset includes a review of where the HCV field now stands, from the unprecedented levels of efficacy and simplicity in curing individual patients, through to the steps required to advance toward the goal of eradicating HCV across communities and ultimately throughout the world.
Format: Microsoft PowerPoint (.ppt)
File size: 3.07 MB
Date posted: 12/7/2016
  • Why I am Encouraged by Data on NASH Management From the 2016 Boston Hepatology Meeting

    Brent A. Neuschwander-Tetri MD - 3/10/2017    
    The treatment of NASH has challenges not seen in patients with HCV infection, but new trends are emerging.
  • How Data From the 2016 Boston Hepatology Meeting Will Influence Future HCV Patient Management

    Mark S. Sulkowski MD - 1/31/2017    2 comments / Last Comment: 4/24/2017
    The 2016 hepatology meeting in Boston offered future solutions to some of my most vexing patient challenges.
  • How Recent Guideline Updates on HBV Screening in HCV-Infected DAA Recipients Affect Clinical Practice

    Norah Terrault MD, MPH - 11/23/2016    1 comment / Last Comment: 11/29/2016
    How do recent AASLD/IDSA updates on HBV screening change nonspecialist and specialist management of HCV patients? Here’s my take.
  • EASL 2017: Emerging Therapies for Genotype 3 HCV

    Nancy Reau MD, FAASLD, AGAF - 5/12/2017    3 comments / Last Comment: 6/16/2017
    Genotype 3 HCV infection is concerning, not just because of its natural history but also because of its potential role in reinfection. New data from EASL offer promise for the treatment of this challenging patient population.
  • Do HCV DAAs Increase HCC Recurrence Risk or Not?

    Paul Y. Kwo MD - 5/25/2017    4 comments / Last Comment: 6/14/2017
    Here’s my take on new data from EASL 2017.